Legend Biotech Corporation (LEGN)
UndervaluedFundamental
45
Price
$19.89
Market Cap
$3.87B
Part 1 · What the company is worth
Overview
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 19, 2026 with claude-haiku-4-5 — shared with all users
Its BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel) is the other approved cell therapy for relapsed or refractory multiple myeloma, treating the same patients in the same transplant centres as Carvykti.
Through its Kite unit — and after buying Arcellx in April 2026 — it is bringing anito-cel, a BCMA CAR-T aimed squarely at the myeloma patients Carvykti treats, to market with a safety profile pitched at outpatient use.
Its bispecific antibody Elrexfio (elranatamab) hits the same BCMA target in the same late-line myeloma setting, and is an off-the-shelf alternative for patients who cannot wait for a CAR-T to be manufactured.
Its BCMAxCD3 bispecific Lynozyfic (linvoseltamab) competes for the same relapsed or refractory myeloma prescriptions, with a dosing schedule that thins out over time to hold patients on therapy.
Balance Sheet & Liquidity
Revenue
$1.27B
Trailing 12 months (through 6/30/2026)
Net Income
$-92M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$27M
Total Equity
$1.23B
Total Liabilities
$278M
Current Ratio
3.04
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$27.60
Current Price
$19.89
Margin of Safety
+27.9%
Fair Value Range
$17.94 - $37.25
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-8.1%
P/B Ratio
3.13
P/FCF
142.26
Gross Margin
56.6%
ROIC
9.9%
Profitability Radar
Value Creation (Economic Moat)
ROIC
9.9%
WACC
7.4%
ROIC − WACC
+2.5 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (7)
- ROIC 9.9%
- Gross Margin 56.6%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 68.8%
- Analyst Consensus 74% Buy
Failed (9)
- Price CAGR -6.81%
- P/FCF 142.26
- P/B Ratio 3.13
- CapEx intensity
- DCF valuation (Overvalued)
- ROE -8.7%
- Earnings Surprise avg -339.9%
- Net Margin Trend -28.8% vs -28.2%
- Piotroski F-Score 1/9
Unavailable (11)
- EPS data insufficient
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Carlos Santos Garcia | Chief Financial Officer | 53 |
| Ms. Ananda Elizabeth Martin Esq., J.D. | Global Compliance Officer | 51 |
| Mr. Robert Staloff | General Counsel | - |
| Dr. Ying Huang Ph.D. | Advisor | 52 |
| Dr. Yuhong Qiu Ph.D. | Interim Head of Research & Development and Senior VP of Regulatory Affairs | - |
| Mr. Birk Vanderweeen | Senior Vice President of Global Manufacturing & Supply | - |
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for LEGN, sourced from Markets Gazette.
- 6/18/2026NEGATIVEWhy Is Legend Biotech Stock Falling Thursday?
Legend Biotech Corporation (LEGN) experienced a premarket decline following the announcement of a $226 million public offering. While the offering aims to raise capital, the dilution effect of issuing new shares typically puts downward pressure on the stock price in the short term. Investors will be monitoring the use of these funds and the company's future growth prospects to assess the long-term impact of this capital raise. The immediate reaction suggests market participants are factoring in the increased share count.
via Markets Gazette